Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

原发难治老年B-ALL患者CD19 CAR-T联合来那度胺治疗后长期生存1例

尹青松,宋永平,苏燕,艾昊,熊媛媛,王倩,魏旭东

Chinese Clinical Oncology（2021）

Cited 0|Views11
No score
Abstract
急性淋巴细胞白血病( acute lymphoblastic leukemia, ALL)是常见的造血系统恶性肿瘤,其发生于老年患者可因老年人群机体功能减退等导致治疗更为困难,预后更差,且一旦复发或难治( R/R) ,常规化疗再缓解率极低.本例老年B细胞-ALL(B-ALL)患者原发耐药,CD19嵌合抗原受体 T细胞(CAR-T)免疫治疗后采用来那度胺联合白介素-2(IL-2)维持治疗,目前已持续微小残留病( MRD)阴性完全缓解( CR)超过45个月.现报告如下.
More
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined